Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.
PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.
Join us at this year s conference as we celebrate the unwavering commitment and resilience of our oncology heroes, depicted through a captivating display.